Leaflet FIGOZAP 10mg film-coated tablets
- Product code:
- W71611001
- Quantity:
- 10
- Indicated for:
- type 2 diabetes; heart failure; chronic kidney disease
- Route of administration:
- oral
- Substance:
- dapagliflozin (SGLT2 inhibitor)
- ATC
- A10BK01 — Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Dapagliflozin is indicated in adults and children aged 10 years and older for the treatment of insufficiently controlled type 2 diabetes mellitus, in combination with diet and exercise:
- as monotherapy, when metformin is inappropriate due to intolerance.
- in combination with other medicinal products for the treatment of type 2 diabetes mellitus.
Dapagliflozin is indicated for the treatment of symptomatic adult patients with chronic heart failure.
Dapagliflozin is indicated for the treatment of adult patients with chronic kidney disease.
Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2.
SGLT2 inhibition by dapagliflozin reduces glucose reabsorption from the glomerular filtrate at the proximal tubule level, with concomitant reduction in sodium reabsorption, leading to urinary glucose excretion and osmotic diuresis.
Dapagliflozin improves both fasting and postprandial blood glucose levels by reducing renal glucose reabsorption, followed by its urinary excretion.
- as monotherapy, when metformin is inappropriate due to intolerance.
- in combination with other medicinal products for the treatment of type 2 diabetes mellitus.
Dapagliflozin is indicated for the treatment of symptomatic adult patients with chronic heart failure.
Dapagliflozin is indicated for the treatment of adult patients with chronic kidney disease.
Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2.
SGLT2 inhibition by dapagliflozin reduces glucose reabsorption from the glomerular filtrate at the proximal tubule level, with concomitant reduction in sodium reabsorption, leading to urinary glucose excretion and osmotic diuresis.
Dapagliflozin improves both fasting and postprandial blood glucose levels by reducing renal glucose reabsorption, followed by its urinary excretion.
General data about FIGOZAP 10mg
- Substance:
- dapagliflozin
- Date of latest medicines list:
- 01-02-2026
- Product code:
- W71611001
- Concentration:
- 10mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 10
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for dapagliflozin
- 10mg
- 5mg